Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

  • Revenue in USD (TTM)53.19bn
  • Net income in USD12.86bn
  • Incorporated1996
  • Employees75.88k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVN:SWX since
announced
Transaction
value
Regulus Therapeutics IncDeal completed30 Apr 202530 Apr 2025Deal completed2.14%1.62bn
Anthos Therapeutics IncDeal completed11 Feb 202511 Feb 2025Deal completed-0.73%3.08bn
Data delayed at least 15 minutes, as of Jul 11 2025 16:31 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gilead Sciences Inc28.74bn5.97bn136.38bn17.60k23.197.1215.614.754.734.7322.7915.390.50983.456.351,632,671.0010.585.2613.636.3878.2978.4720.7612.541.237.800.5667108.476.045.08-91.53-38.34-8.714.10
Pfizer Inc62.46bn7.87bn145.83bn81.00k18.611.619.862.331.381.3810.9515.890.29111.465.47771,148.103.687.454.499.4374.5769.1012.6420.370.960412.260.406664.226.849.10275.82-5.272.323.13
Amgen Inc34.13bn5.93bn158.77bn28.00k26.9525.5813.764.6510.9610.9663.0511.540.37431.594.581,218,786.006.518.438.5010.6664.0772.8117.3921.900.8787.060.902471.3718.577.43-39.11-12.2112.149.18
Merck & Co Inc63.92bn17.43bn209.32bn75.00k12.134.349.473.276.876.8725.1919.210.57862.315.77852,293.3015.799.5220.4612.6477.0773.4727.3017.871.1623.900.418672.966.7410.404,589.5924.64-0.58856.66
Novartis AG (ADR)53.19bn12.86bn255.09bn75.88k18.956.1813.484.806.396.3926.4019.580.54752.246.47700,908.0013.249.8019.3113.0875.6673.7624.1824.420.609717.410.4478--10.851.2439.3710.8311.06--
AbbVie Inc57.37bn4.16bn339.94bn55.00k82.06239.3826.955.932.352.3532.390.8040.40253.834.701,043,036.002.955.444.067.0970.6968.897.3313.730.63597.800.9795134.963.7111.11-12.07-11.5812.037.69
Johnson & Johnson89.33bn21.81bn377.51bn138.10k17.444.8312.974.238.998.9936.8332.470.48862.355.77646,857.4011.938.6316.7811.7368.3468.7024.4118.291.03--0.400874.744.301.605.55-1.434.815.54
Data as of Jul 11 2025. Currency figures normalised to Novartis AG's reporting currency: US Dollar USD

Institutional shareholders

2.70%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Mar 202511.82m0.54%
PRIMECAP Management Co.as of 31 Mar 202510.38m0.47%
Dimensional Fund Advisors LPas of 31 Mar 20257.58m0.35%
Fisher Asset Management LLCas of 31 Mar 20256.76m0.31%
Loomis, Sayles & Co. LPas of 31 Mar 20255.50m0.25%
Franklin Mutual Advisers LLCas of 31 Mar 20254.86m0.22%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 20253.52m0.16%
Parametric Portfolio Associates LLCas of 31 Mar 20253.00m0.14%
Managed Account Advisors LLCas of 31 Mar 20252.91m0.13%
Wellington Management Co. LLPas of 31 Mar 20252.82m0.13%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.